Skip to main content
Erschienen in: Virchows Archiv 4/2013

01.04.2013 | Original Article

Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens

verfasst von: Amanda H. Seipel, Fredrik Wiklund, N Peter Wiklund, Lars Egevad

Erschienen in: Virchows Archiv | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Ductal adenocarcinoma (DAC) of the prostate is thought to have worse prognosis than prostatic acinar carcinoma (PAC). We aimed to evaluate the prognostic significance of histopathological patterns of DAC. A series of 1,051 radical prostatectomy specimens from Karolinska University Hospital 1998–2005 was reviewed. A ductal component was classified as classical DAC (DACC) if it had columnar, pseudostratified epithelium, elongated nuclei, and papillary, glandular, or cribriform architecture; borderline DAC (DACB) if it lacked elongated nuclei or classical architecture; and prostatic adenocarcinoma with ductal features (PCDF) if stratified high-grade nuclei were found. DACC, DACB, and PCDF were seen in 2.6, 4.0, and 1.6 % of the cases. DAC was usually mixed with PAC and constituted 10–100 % (mean 40 %) of the main tumor. Location was periurethral, peripheral, or both in 69.8, 3.5, and 26.7 %. Necrosis was seen in 31.3 %, stromal invasion of DAC in 52.3 %, and intraductal spread in 91.9 %. In DACC/DACB and PAC, extraprostatic extension was seen in 66.7 and 42.4 % (p < 0.001) and seminal vesicle invasion in 13.0 and 5.0 % (p = 0.0045). DACC, DACB, and PCDF had a hazard ratio for biochemical recurrence of 1.5 (0.7–2.8), 1.4 (0.8–2.6) and 1.2 (0.5–2.7). When PCDF was excluded from DAC, hazard ratio was 1.4 (95 % CI 0.9–2.3, p = 0.12). Location, % DAC, necrosis, stromal invasion, or Gleason score were not predictive of recurrence. This suggests that DACC and DACB are more aggressive than average PAC, while cancers with acinar architecture and pseudostratified high-grade nuclei should not be included in DAC.
Literatur
1.
Zurück zum Zitat Melicow MM, Pachter MR (1967) Endometrial carcinoma of proxtatic utricle (uterus masculinus). Cancer 20:1715–1722PubMedCrossRef Melicow MM, Pachter MR (1967) Endometrial carcinoma of proxtatic utricle (uterus masculinus). Cancer 20:1715–1722PubMedCrossRef
2.
Zurück zum Zitat Bock BJ, Bostwick DG (1999) Does prostatic ductal adenocarcinoma exist? Am J Surg Pathol 23:781–785PubMedCrossRef Bock BJ, Bostwick DG (1999) Does prostatic ductal adenocarcinoma exist? Am J Surg Pathol 23:781–785PubMedCrossRef
3.
Zurück zum Zitat Gong Y, Caraway N, Stewart J, Staerkel G (2006) Metastatic ductal adenocarcinoma of the prostate: cytologic features and clinical findings. Am J Clin Pathol 126:302–309PubMedCrossRef Gong Y, Caraway N, Stewart J, Staerkel G (2006) Metastatic ductal adenocarcinoma of the prostate: cytologic features and clinical findings. Am J Clin Pathol 126:302–309PubMedCrossRef
4.
Zurück zum Zitat Millar EK, Sharma NK, Lessells AM (1996) Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathological study of 16 cases. Histopathology 29:11–19PubMedCrossRef Millar EK, Sharma NK, Lessells AM (1996) Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathological study of 16 cases. Histopathology 29:11–19PubMedCrossRef
5.
Zurück zum Zitat Orihuela E, Green JM (2008) Ductal prostate cancer: contemporary management and outcomes. Urol Oncol 26:368–371PubMedCrossRef Orihuela E, Green JM (2008) Ductal prostate cancer: contemporary management and outcomes. Urol Oncol 26:368–371PubMedCrossRef
6.
Zurück zum Zitat Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL (2009) Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer 115:2872–2880PubMedCrossRef Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL (2009) Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer 115:2872–2880PubMedCrossRef
7.
Zurück zum Zitat Brinker DA, Potter SR, Epstein JI (1999) Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol 23:1471–1479PubMedCrossRef Brinker DA, Potter SR, Epstein JI (1999) Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol 23:1471–1479PubMedCrossRef
8.
Zurück zum Zitat Morgan TM, Welty CJ, Vakar-Lopez F, Lin DW, Wright JL (2010) Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J Urol 184:2303–2307PubMedCrossRef Morgan TM, Welty CJ, Vakar-Lopez F, Lin DW, Wright JL (2010) Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J Urol 184:2303–2307PubMedCrossRef
9.
Zurück zum Zitat Samaratunga H, Delahunt B (2008) Ductal adenocarcinoma of the prostate: current opinion and controversies. Anal Quant Cytol Histol 30:237–246PubMed Samaratunga H, Delahunt B (2008) Ductal adenocarcinoma of the prostate: current opinion and controversies. Anal Quant Cytol Histol 30:237–246PubMed
10.
Zurück zum Zitat Christensen WN, Steinberg G, Walsh PC, Epstein JI (1991) Prostatic duct adenocarcinoma. Findings at radical prostatectomy. Cancer 67:2118–2124PubMedCrossRef Christensen WN, Steinberg G, Walsh PC, Epstein JI (1991) Prostatic duct adenocarcinoma. Findings at radical prostatectomy. Cancer 67:2118–2124PubMedCrossRef
11.
Zurück zum Zitat Eble JN, Sauter G, Epstein JI (2004) Sesterhenn IA (2004) Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC, Lyon Eble JN, Sauter G, Epstein JI (2004) Sesterhenn IA (2004) Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC, Lyon
12.
Zurück zum Zitat Samaratunga H, Duffy D, Yaxley J, Delahunt B (2010) Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. Hum Pathol 41:281–285PubMedCrossRef Samaratunga H, Duffy D, Yaxley J, Delahunt B (2010) Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. Hum Pathol 41:281–285PubMedCrossRef
13.
Zurück zum Zitat Jonmarker S, Glaessgen A, Culp WD, Pisa P, Lewensohn R, Ekman P, Valdman A, Egevad L (2008) Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue. APMIS 116:491–498PubMedCrossRef Jonmarker S, Glaessgen A, Culp WD, Pisa P, Lewensohn R, Ekman P, Valdman A, Egevad L (2008) Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue. APMIS 116:491–498PubMedCrossRef
14.
Zurück zum Zitat Dube VE, Farrow GM, Greene LF (1973) Prostatic adenocarcinoma of ductal origin. Cancer 32:402–409PubMedCrossRef Dube VE, Farrow GM, Greene LF (1973) Prostatic adenocarcinoma of ductal origin. Cancer 32:402–409PubMedCrossRef
15.
Zurück zum Zitat Kuhajda FP, Gipson T, Mendelsohn G (1984) Papillary adenocarcinomas of the prostate. An immunohistochemical study. Cancer 54:1328–1332PubMedCrossRef Kuhajda FP, Gipson T, Mendelsohn G (1984) Papillary adenocarcinomas of the prostate. An immunohistochemical study. Cancer 54:1328–1332PubMedCrossRef
16.
Zurück zum Zitat Samaratunga H, Singh M (1997) Distribution pattern of basal cells detected by cytokeratin 34 beta E12 in primary prostatic duct adenocarcinoma. Am J Surg Pathol 21:435–440PubMedCrossRef Samaratunga H, Singh M (1997) Distribution pattern of basal cells detected by cytokeratin 34 beta E12 in primary prostatic duct adenocarcinoma. Am J Surg Pathol 21:435–440PubMedCrossRef
17.
Zurück zum Zitat Bostwick DG, Kindrachuk RW, Rouse RV (1985) Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am J Surg Pathol 9:595–609PubMedCrossRef Bostwick DG, Kindrachuk RW, Rouse RV (1985) Prostatic adenocarcinoma with endometrioid features. Clinical, pathologic, and ultrastructural findings. Am J Surg Pathol 9:595–609PubMedCrossRef
18.
Zurück zum Zitat Epstein JI, Woodruff JM (1986) Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases. Cancer 57:111–119PubMedCrossRef Epstein JI, Woodruff JM (1986) Adenocarcinoma of the prostate with endometrioid features. A light microscopic and immunohistochemical study of ten cases. Cancer 57:111–119PubMedCrossRef
19.
Zurück zum Zitat Eade TN, Al-Saleem T, Horwitz EM, Buyyounouski MK, Chen DY, Pollack A (2007) Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. Cancer 109:2011–2015PubMedCrossRef Eade TN, Al-Saleem T, Horwitz EM, Buyyounouski MK, Chen DY, Pollack A (2007) Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. Cancer 109:2011–2015PubMedCrossRef
20.
Zurück zum Zitat Pickup M, Van der Kwast TH (2007) My approach to intraductal lesions of the prostate gland. J Clin Pathol 60:856–865PubMedCrossRef Pickup M, Van der Kwast TH (2007) My approach to intraductal lesions of the prostate gland. J Clin Pathol 60:856–865PubMedCrossRef
21.
Zurück zum Zitat Lee TK, Miller JS, Epstein JI (2010) Rare histological patterns of prostatic ductal adenocarcinoma. Pathology 42:319–324PubMedCrossRef Lee TK, Miller JS, Epstein JI (2010) Rare histological patterns of prostatic ductal adenocarcinoma. Pathology 42:319–324PubMedCrossRef
22.
Zurück zum Zitat Vale JA, Patel A, Ball AJ, Hendry WF, Chappell ME, Fisher C (1992) Endometrioid carcinoma of the prostate: a misnomer? J R Soc Med 85:394–396PubMed Vale JA, Patel A, Ball AJ, Hendry WF, Chappell ME, Fisher C (1992) Endometrioid carcinoma of the prostate: a misnomer? J R Soc Med 85:394–396PubMed
23.
24.
Zurück zum Zitat Lee SS (1994) Endometrioid adenocarcinoma of the prostate: a clinicopathologic and immunohistochemical study. J Surg Oncol 55:235–238PubMedCrossRef Lee SS (1994) Endometrioid adenocarcinoma of the prostate: a clinicopathologic and immunohistochemical study. J Surg Oncol 55:235–238PubMedCrossRef
25.
Zurück zum Zitat Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL (2000) Tumors of the Prostate Gland, Seminal Vesicles, Male Urethra and Penis. Armed Forces Institute of Pathology, Washington D.C. 2000 Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL (2000) Tumors of the Prostate Gland, Seminal Vesicles, Male Urethra and Penis. Armed Forces Institute of Pathology, Washington D.C. 2000
26.
Zurück zum Zitat Epstein JI, Allsbrook WC Jr, Amin MB, Egevad L (2006) Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol 13:57–59PubMedCrossRef Epstein JI, Allsbrook WC Jr, Amin MB, Egevad L (2006) Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol 13:57–59PubMedCrossRef
Metadaten
Titel
Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens
verfasst von
Amanda H. Seipel
Fredrik Wiklund
N Peter Wiklund
Lars Egevad
Publikationsdatum
01.04.2013
Verlag
Springer-Verlag
Erschienen in
Virchows Archiv / Ausgabe 4/2013
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-013-1385-5

Weitere Artikel der Ausgabe 4/2013

Virchows Archiv 4/2013 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …